BVS Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -3.47% compared to Bioventus's net margin of --. Bioventus's return on equity of -18.97% beat Perspective Therapeutics's return on equity of --.

Bioventus has a consensus price target of $15.00, signalling upside risk potential of 61.64%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 361.43%. Given that Perspective Therapeutics has higher upside potential than Bioventus, analysts believe Perspective Therapeutics is more attractive than Bioventus.

Bioventus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.546%.

Bioventus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Bioventus quarterly revenues are $139M, which are larger than Perspective Therapeutics quarterly revenues of --. Bioventus's net income of -$4.8M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Bioventus's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus is 1.07x versus 18.90x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -3.47% compared to Bioventus's net margin of 14.25%. Bioventus's return on equity of -18.97% beat Insulet's return on equity of 49.55%.

Bioventus has a consensus price target of $15.00, signalling upside risk potential of 61.64%. On the other hand Insulet has an analysts' consensus of $292.08 which suggests that it could grow by 8.03%. Given that Bioventus has higher upside potential than Insulet, analysts believe Bioventus is more attractive than Insulet.

Bioventus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insulet has a beta of 1.218, suggesting its more volatile than the S&P 500 by 21.787%.

Bioventus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Bioventus quarterly revenues are $139M, which are smaller than Insulet quarterly revenues of $543.9M. Bioventus's net income of -$4.8M is lower than Insulet's net income of $77.5M. Notably, Bioventus's price-to-earnings ratio is -- while Insulet's PE ratio is 46.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus is 1.07x versus 10.41x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -3.47% compared to Bioventus's net margin of 25.43%. Bioventus's return on equity of -18.97% beat ResMed's return on equity of 23.76%.

Bioventus has a consensus price target of $15.00, signalling upside risk potential of 61.64%. On the other hand ResMed has an analysts' consensus of -- which suggests that it could grow by 8.54%. Given that Bioventus has higher upside potential than ResMed, analysts believe Bioventus is more attractive than ResMed.

Bioventus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ResMed has a beta of 0.698, suggesting its less volatile than the S&P 500 by 30.155%.

Bioventus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.86% to investors and pays a quarterly dividend of $0.53 per share. Bioventus pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bioventus quarterly revenues are $139M, which are smaller than ResMed quarterly revenues of $1.2B. Bioventus's net income of -$4.8M is lower than ResMed's net income of $311.4M. Notably, Bioventus's price-to-earnings ratio is -- while ResMed's PE ratio is 31.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus is 1.07x versus 7.25x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -3.47% compared to Bioventus's net margin of -17.98%. Bioventus's return on equity of -18.97% beat Xtant Medical Holdings's return on equity of -35.98%.

Bioventus has a consensus price target of $15.00, signalling upside risk potential of 61.64%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 381.39%. Given that Xtant Medical Holdings has higher upside potential than Bioventus, analysts believe Xtant Medical Holdings is more attractive than Bioventus.

Bioventus has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

Bioventus has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bioventus pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Bioventus quarterly revenues are $139M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. Bioventus's net income of -$4.8M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Bioventus's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bioventus is 1.07x versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.